Please use this identifier to cite or link to this item:
http://nopr.niscpr.res.in/handle/123456789/33808| Title: | Role of protein tyrosine kinase inhibitors in cancer therapeutics |
| Authors: | Bhise, S B Nalawade, Abhijit D Wadhawa, Hitesh |
| Keywords: | Protein tyrosine kinase;Tyrosine kinase inhibitors;Imatinib mesylate;Chronic myeloid leukemia;Acute myeloid leukemia;Anticancer agent;Gastrointestinal stromal tumor;Epidermal growth factor receptor;Vascular endothelial growth factor |
| Issue Date: | Dec-2004 |
| Publisher: | NISCAIR-CSIR, India |
| Abstract: | Protein tyrosine kinases (PTKs) are critical in regulating cell growth and differentiation and are deeply involved in several cancers. PTK-inhibitors are mainly ATP-site directed and are finding use in the treatment of several cancers, and more than 30 such agents are now in phase I-III clinical trials. The present review focuses mainly on the development of PTK inhibitors in clinical trials, with special emphasis on imatinib mesylate, a rationally designed, potent oral anticancer agent and selective inhibitor for Abl tyrosine kinase, including Bcr-Abl, C-kit and platelet-derived growth factor-receptor tyrosine kinases, which has been implicated in several malignancies, including chronic myeloid leukemia and gastrointestinal stromal tumour. |
| Page(s): | 273-280 |
| ISSN: | 0975-0959 (Online); 0301-1208 (Print) |
| Appears in Collections: | IJBB Vol.41(6) [December 2004] |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| IJBB 41(6) 273-280.pdf | 1.78 MB | Adobe PDF | View/Open |
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.